Molecular Features and Clinical Management of Hereditary Gynecological Cancers
Hereditary gynecological cancers are caused by several inherited genes. Tumors that arise in the female reproductive system, such as ovaries and the uterus, overlap with hereditary cancers. Several hereditary cancer-related genes are important because they might lead to therapeutic targets. Treatmen...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/24/9504 |
| _version_ | 1797544747175247872 |
|---|---|
| author | Arisa Ueki Akira Hirasawa |
| author_facet | Arisa Ueki Akira Hirasawa |
| author_sort | Arisa Ueki |
| collection | DOAJ |
| description | Hereditary gynecological cancers are caused by several inherited genes. Tumors that arise in the female reproductive system, such as ovaries and the uterus, overlap with hereditary cancers. Several hereditary cancer-related genes are important because they might lead to therapeutic targets. Treatment of hereditary cancers should be updated in line with the advent of various new methods of evaluation. Next-generation sequencing has led to rapid, economical genetic analyses that have prompted a concomitant and significant paradigm shift with respect to hereditary cancers. Molecular tumor profiling is an epochal method for determining therapeutic targets. Clinical treatment strategies are now being designed based on biomarkers based on tumor profiling. Furthermore, the National Comprehensive Cancer Network (NCCN) guidelines significantly changed the genetic testing process in 2020 to initially consider multi-gene panel (MGP) evaluation. Here, we reviewed the molecular features and clinical management of hereditary gynecological malignancies, such as hereditary breast and ovarian cancer (HBOC), and Lynch, Li–Fraumeni, Cowden, and Peutz–Jeghers syndromes. We also reviewed cancer-susceptible genes revealed by MGP tests. |
| first_indexed | 2024-03-10T14:04:47Z |
| format | Article |
| id | doaj.art-551a76fe92f144cbbf92d5399b69051b |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T14:04:47Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-551a76fe92f144cbbf92d5399b69051b2023-11-21T00:44:11ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-12-012124950410.3390/ijms21249504Molecular Features and Clinical Management of Hereditary Gynecological CancersArisa Ueki0Akira Hirasawa1Center for Medical Genetics, Keio Cancer Center, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JapanDepartment of Clinical Genomic Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, JapanHereditary gynecological cancers are caused by several inherited genes. Tumors that arise in the female reproductive system, such as ovaries and the uterus, overlap with hereditary cancers. Several hereditary cancer-related genes are important because they might lead to therapeutic targets. Treatment of hereditary cancers should be updated in line with the advent of various new methods of evaluation. Next-generation sequencing has led to rapid, economical genetic analyses that have prompted a concomitant and significant paradigm shift with respect to hereditary cancers. Molecular tumor profiling is an epochal method for determining therapeutic targets. Clinical treatment strategies are now being designed based on biomarkers based on tumor profiling. Furthermore, the National Comprehensive Cancer Network (NCCN) guidelines significantly changed the genetic testing process in 2020 to initially consider multi-gene panel (MGP) evaluation. Here, we reviewed the molecular features and clinical management of hereditary gynecological malignancies, such as hereditary breast and ovarian cancer (HBOC), and Lynch, Li–Fraumeni, Cowden, and Peutz–Jeghers syndromes. We also reviewed cancer-susceptible genes revealed by MGP tests.https://www.mdpi.com/1422-0067/21/24/9504hereditary gynecological cancermulti-gene testingtumor profilinghereditary breast and ovarian cancer (HBOC)LynchLi–Fraumeni |
| spellingShingle | Arisa Ueki Akira Hirasawa Molecular Features and Clinical Management of Hereditary Gynecological Cancers International Journal of Molecular Sciences hereditary gynecological cancer multi-gene testing tumor profiling hereditary breast and ovarian cancer (HBOC) Lynch Li–Fraumeni |
| title | Molecular Features and Clinical Management of Hereditary Gynecological Cancers |
| title_full | Molecular Features and Clinical Management of Hereditary Gynecological Cancers |
| title_fullStr | Molecular Features and Clinical Management of Hereditary Gynecological Cancers |
| title_full_unstemmed | Molecular Features and Clinical Management of Hereditary Gynecological Cancers |
| title_short | Molecular Features and Clinical Management of Hereditary Gynecological Cancers |
| title_sort | molecular features and clinical management of hereditary gynecological cancers |
| topic | hereditary gynecological cancer multi-gene testing tumor profiling hereditary breast and ovarian cancer (HBOC) Lynch Li–Fraumeni |
| url | https://www.mdpi.com/1422-0067/21/24/9504 |
| work_keys_str_mv | AT arisaueki molecularfeaturesandclinicalmanagementofhereditarygynecologicalcancers AT akirahirasawa molecularfeaturesandclinicalmanagementofhereditarygynecologicalcancers |